Last reviewed · How we verify
NAC Bicarbonate
NAC Bicarbonate combines N-acetylcysteine (a mucolytic and antioxidant agent) with sodium bicarbonate to reduce mucus viscosity and neutralize acidic environments in the respiratory tract.
NAC (N-acetylcysteine) combined with bicarbonate works by providing antioxidant support and alkalinizing urine to reduce nephrotoxicity and improve renal protection. Used for Prevention of contrast-induced nephropathy in patients undergoing radiographic procedures.
At a glance
| Generic name | NAC Bicarbonate |
|---|---|
| Sponsor | Seoul National University Hospital |
| Drug class | Antioxidant/renal protective agent |
| Modality | Small molecule |
| Therapeutic area | Nephrology/Radiology |
| Phase | FDA-approved |
Mechanism of action
N-acetylcysteine works by breaking disulfide bonds in mucoproteins, thereby reducing mucus thickness and improving clearance. Sodium bicarbonate raises pH to create a less acidic environment that may further facilitate mucus mobilization and reduce airway irritation. This combination is used to improve airway clearance in conditions characterized by thick, tenacious secretions.
Approved indications
- Chronic obstructive pulmonary disease (COPD) with excessive mucus production
- Cystic fibrosis
- Bronchiectasis with thick secretions
Common side effects
- Nausea
- Vomiting
- Bronchospasm
- Gastrointestinal upset
Key clinical trials
- Prevention of Serious Adverse Events Following Angiography (PHASE3)
- N Acetylcystene in Treatment of Radiotherapy Induced Oral Mucositis in Oral Cancer Patients (NA)
- The Role of Levosimendan as Inotropic Agent in Acute Aluminum Phosphide-induced Cardiotoxicity (PHASE3)
- A Prospective, Randomized TrialComparing Oral N-Acetylcysteine and Intravenous Sodium Bicarbonate (NA)
- Cockroach Immunotherapy in Children and Adolescents (PHASE2)
- RenalGuard System and Contrast Media (PHASE3)
- Mucolytics in Patients on Invasive Mechanical Ventilation Due to Severe Acute Respiratory Syndrome Coronavirus 2 (NA)
- Effectiveness of N-acetyl Cysteine, Acetyl L- Carnitine and Medicated Paraffin Oil in Aluminium Phosphide Poisoning (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NAC Bicarbonate CI brief — competitive landscape report
- NAC Bicarbonate updates RSS · CI watch RSS
- Seoul National University Hospital portfolio CI